Novel Metabolic Tumor Marker

A metabolic marker has shown the ability to identify different malignancies with high sensitivity and a specificity of 90-95%. The marker quantifies a tumor-specific enzyme called tumor M2-PK.

The majority of human tumors strongly overexpress an isoform of the glycolytic enzyme pyruvate kinase, tumor M2-PK, which is quantitatively detectable in body fluids. The concentration of this tumor metabolic marker correlates with the tumor stage, indicating a strong association with the tumor load. tumors. Thus, the marker reflects tumor regression and progression during chemotherapy and is suitable for disease monitoring and therapy control.

ScheBo Biotech AG (Giessen, Germany) has developed a highly sensitive enzyme-linked immunosorbent assay (ELISA) that allows measurement of M2-PK in EDTA plasma. The M2-PK test is based on two monoclonal antibodies that specifically react with tumor M2-PK and do not cross-react with the other isoforms of pyruvate kinase. The results of clinical studies show the test is well-suited for identifying gastrointestinal tumors (colon, rectal, gastric, esophageal, and pancreatic cancer). The company notes the test can also be used to identify breast, bronchial, and lung cancer.

ScheBo Biotech develops, produces, and globally distributes test systems for human and veterinary diagnostics as well as for food analysis.



Related Links:
ScheBo